Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
RESEARCH ARTICLE

Condom migration resulting from circumcision, microbicides and vaccines: brief review and methodological considerations

Richard A. Crosby A B D , JaNelle Ricks A and April Young C
+ Author Affiliations
- Author Affiliations

A College of Public Health, University of Kentucky, 111 Washington Avenue, Lexington, KY 40536-0003, USA.

B Kinsey Institute for Research on Sex, Gender, and Reproduction, Morrison 313, 1165 E. Third Street, Bloomington, IN 47405, USA.

C Rollins School of Public Health, Department of Behavioral Sciences & Health Education, Emory University, 1518 Clifton Road, Atlanta, GA 30322, USA.

D Corresponding author. Email: crosby@uky.edu

Sexual Health 9(1) 96-102 https://doi.org/10.1071/SH11091
Submitted: 28 June 2011  Accepted: 13 September 2011   Published: 17 February 2012

Abstract

Objective: To provide an updated review of condom migration as a means of highlighting methodological issues for future studies of this behavioural issue. Methods: Electronic searches of PubMed, MEDLINE and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases were carried out in October 2010 and updated in January 2011 for English-language articles published from 1994 onward. Results:Evidence addressing condom migration from microbicides and vaccines is vastly underdeveloped, simply because these products are still experimental. In contrast, the more advanced evidence regarding male circumcision is hopeful because it suggests that migration may not be an overwhelming issue. Nonetheless, the entire body of empirical evidence on this question could be substantially expanded and improved. Conclusion: Until stronger evidence suggests that condom migration is unlikely, it is important to be mindful of the potential for condom migration to occur in response to biomedical interventions (circumcision, microbicides and vaccines).

Additional keywords: condom use, contraceptives, risk, safer sex.


References

[1]  Cassell MM, et al Risk compensation: the Achilles’ heel of innovations in HIV prevention? BMJ (Int Ed) 2006; 332 605–607.

[2]  Novak DP, Karlsson RB. Gender differed factors affecting male condom use. A population-based study of 18-year-old Swedish adolescents. Int J Adolesc Med Health 2005; 17 379–90.
Gender differed factors affecting male condom use. A population-based study of 18-year-old Swedish adolescents.CrossRef |

[3]  Roye CF. Condom use by Hispanic and African-American adolescent girls who use hormonal contraception. J Adolesc Health 1998; 23 205–11.
Condom use by Hispanic and African-American adolescent girls who use hormonal contraception.CrossRef | 1:STN:280:DyaK1cvjsVWhsg%3D%3D&md5=b42343928648cc8056da945a3fdfaaf1CAS |

[4]  Sangi-Haghpeykar H, Posner SF, Poindexter AN. Consistency of condom use among low-income hormonal contraceptive users. Perspect Sex Reprod Health 2005; 37 184–91.
Consistency of condom use among low-income hormonal contraceptive users.CrossRef |

[5]  Sieving R, et al Cognitive and behavioral predictors of sexually transmitted disease risk behavior among sexually active adolescents. Arch Pediatr Adolesc Med 1997; 151 243–51.
| 1:STN:280:DyaK2s3js1SisA%3D%3D&md5=5be8faa52ede29808a7d86d861b30869CAS |

[6]  Smith JL, et al Young males’ perspectives on pregnancy, fatherhood and condom use: where does responsibility for birth control lie? Sex Reprod Healthc 2011; 2 37–42.
Young males’ perspectives on pregnancy, fatherhood and condom use: where does responsibility for birth control lie?CrossRef |

[7]  Weisman CS, et al Consistency of condom use for disease prevention among adolescent users of oral contraceptives. Fam Plann Perspect 1991; 23 71–4.
Consistency of condom use for disease prevention among adolescent users of oral contraceptives.CrossRef | 1:STN:280:DyaK3M3osFSrtw%3D%3D&md5=b874da56db1c515ad0478e9ea48af1faCAS |

[8]  Cates W, Holmes KK, Sparling PF, Mardh P. Contraception, contraceptive technology, and STDs. Sex Transm Dis 1999; 3 1067–78.

[9]  Rosenthal SL, et al Experience with side effects and health risks associated with Norplant implant use in adolescents. Contraception 1995; 52 283–5.
Experience with side effects and health risks associated with Norplant implant use in adolescents.CrossRef | 1:CAS:528:DyaK28XotlCl&md5=31563c1a420137e48f05379ecf9abd1bCAS |

[10]  Pruitt SL, et al Condom use among sterilized and nonsterilized women in county jail and residential treatment centers. Womens Health Issues 2010; 20 386–93.
Condom use among sterilized and nonsterilized women in county jail and residential treatment centers.CrossRef |

[11]  Sangi-Haghpeykar H, Horth F, Poindexter AN. Condom use among sterilized and nonsterilized Hispanic women. Sex Transm Dis 2001; 28 546–51.
Condom use among sterilized and nonsterilized Hispanic women.CrossRef | 1:STN:280:DC%2BD3MvnsFGltw%3D%3D&md5=c2f981f361574ad7248f028d3616026eCAS |

[12]  Semaan S, Lauby J, Walls C. Condom use with main partners by sterilized and non-sterilized women. Women Health Issues 1997; 25 65–85.
Condom use with main partners by sterilized and non-sterilized women.CrossRef | 1:STN:280:DyaK2svisVyktA%3D%3D&md5=779fef4be62c2e36181045a1225f6ec4CAS |

[13]  Behets F, et al Acceptability and feasibility of continuous diaphragm use among sex workers in Madagascar. Sex Transm Infect 2005; 81 472–6.
Acceptability and feasibility of continuous diaphragm use among sex workers in Madagascar.CrossRef | 1:STN:280:DC%2BD2Mnksleiuw%3D%3D&md5=24ae6e5982f6d7da65a3a52fdcbcc56dCAS |

[14]  Behets FM, et al Evidence-based planning of a randomized controlled trial on diaphragm use for prevention of sexually transmitted infections. Sex Transm Dis 2008; 35 238–42.
Evidence-based planning of a randomized controlled trial on diaphragm use for prevention of sexually transmitted infections.CrossRef |

[15]  Gallo MF, et al Assessment of changes in condom use among female sex workers in a prospective cohort study introducing diaphragm use for disease prevention. Am J Epidemiol 2010; 172 606–12.
Assessment of changes in condom use among female sex workers in a prospective cohort study introducing diaphragm use for disease prevention.CrossRef |

[16]  Padian NS, et al Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 2007; 370 251–61.
Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial.CrossRef |

[17]  Posner SF, et al Introducing diaphragms into the mix: what happens to male condom use patterns? AIDS Behav 2005; 9 443–9.
Introducing diaphragms into the mix: what happens to male condom use patterns?CrossRef |

[18]  van der Straten A, et al The use of the diaphragm instead of condoms in a phase III diaphragm trial. AIDS Behav 2009; 13 564–72.
The use of the diaphragm instead of condoms in a phase III diaphragm trial.CrossRef |

[19]  van der Straten A, Cheng H, Minnis AM. Change in condom and other barrier method use during and after an HIV prevention trial in Zimbabwe. J Int AIDS Soc 2010; 13 39–49.
Change in condom and other barrier method use during and after an HIV prevention trial in Zimbabwe.CrossRef |

[20]  Bukusi EA, et al Adherence to diaphragm use for infection prevention: a prospective study of female sex workers in Kenya. Infect Dis Obstet Gynecol 2009; 2009 420196
Adherence to diaphragm use for infection prevention: a prospective study of female sex workers in Kenya.CrossRef |

[21]  Belzer M, et al Advance supply of emergency contraception: a randomized trial in adolescent mothers. J Pediatr Adolesc Gynecol 2005; 18 347–54.
Advance supply of emergency contraception: a randomized trial in adolescent mothers.CrossRef |

[22]  Chin-Quee DS, et al Bridging emergency contraceptive pill users to regular contraception: results from a randomized trial in Jamaica. Contraception 2010; 81 133–9.
Bridging emergency contraceptive pill users to regular contraception: results from a randomized trial in Jamaica.CrossRef |

[23]  Ekstrand M, et al Advance provision of emergency contraceptive pills reduces treatment delay: a randomised controlled trial among Swedish teenage girls. Acta Obstet Gynecol Scand 2008; 87 354–9.
Advance provision of emergency contraceptive pills reduces treatment delay: a randomised controlled trial among Swedish teenage girls.CrossRef |

[24]  Ellertson C, et al Emergency contraception: randomized comparison of advance provision and information only. Obstet Gynecol 2001; 98 570–5.
Emergency contraception: randomized comparison of advance provision and information only.CrossRef | 1:STN:280:DC%2BD3MrjtVKlsg%3D%3D&md5=15e0fd97dc14b483f767e6eec6f3c203CAS |

[25]  Gray RH, et al Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369 657–66.
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.CrossRef |

[26]  Polis CB, et al Advance provision of emergency contraception for pregnancy prevention: a meta-analysis. Obstet Gynecol 2007; 110 1379–88.
Advance provision of emergency contraception for pregnancy prevention: a meta-analysis.CrossRef |

[27]  Walker DM, et al Emergency contraception use is correlated with increased condom use among adolescents: results from Mexico. J Adolesc Health 2004; 35 329–34.
Emergency contraception use is correlated with increased condom use among adolescents: results from Mexico.CrossRef |

[28]  Eaton LA, Kalichman SC. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007; 4 165–72.
Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies.CrossRef |

[29]  Potts MH, Halperin DT, Kirby D, Swidler A, Marseille E, Klausner JD, et al Reassessing HIV prevention. Science 2008; 320 749–50.
Reassessing HIV prevention.CrossRef | 1:CAS:528:DC%2BD1cXmtF2ls7s%3D&md5=e660684c201a958778691ebec0d9a5b3CAS |

[30]  Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. AIDS 2000; 14 2361–70.
Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis.CrossRef | 1:STN:280:DC%2BD3M7ltFGhsg%3D%3D&md5=5ed243b26d372daf2ea6a7a078ac1192CAS |

[31]  Reynolds SJ, et al Male circumcision and risk of HIV-1 and other sexually transmitted infections in India. Lancet 2004; 363 1039–40.
Male circumcision and risk of HIV-1 and other sexually transmitted infections in India.CrossRef |

[32]  Riess TH, et al “When I was circumcised I was taught certain things”: risk compensation and protective sexual behavior among circumcised men in Kisumu, Kenya. PLoS ONE 2010; 5 e12366
“When I was circumcised I was taught certain things”: risk compensation and protective sexual behavior among circumcised men in Kisumu, Kenya.CrossRef |

[33]  Andersson KM, Owens DK, Paltiel AD. Scaling up circumcision programs in southern Africa: the potential impact of gender disparities and changes in condom use behaviors on heterosexual HIV transmission. AIDS Behav 2011; 15 938–48.
Scaling up circumcision programs in southern Africa: the potential impact of gender disparities and changes in condom use behaviors on heterosexual HIV transmission.CrossRef |

[34]  Agot KE, et al Male circumcision in Siaya and Bondo Districts, Kenya: prospective cohort study to assess behavioral disinhibition following circumcision. J Acquir Immune Defic Syndr 2007; 44 66–70.
Male circumcision in Siaya and Bondo Districts, Kenya: prospective cohort study to assess behavioral disinhibition following circumcision.CrossRef |

[35]  Auvert B, et al Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2 e298
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.CrossRef |

[36]  Bailey RC, et al Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369 643–56.
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.CrossRef |

[37]  Ramjee G, et al Acceptability of Carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South Africa. AIDS Res Ther 2007; 4 20–29.
Acceptability of Carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South Africa.CrossRef |

[38]  Foss AM, et al Shifts in condom use following microbicide introduction: should we be concerned? AIDS 2003; 17 1227–37.
Shifts in condom use following microbicide introduction: should we be concerned?CrossRef |

[39]  Guest G, et al Changes in sexual behavior during a safety and feasibility trial of a microbicide/diaphragm combination: an integrated qualitative and quantitative analysis. AIDS Educ Prev 2007; 19 310–20.
Changes in sexual behavior during a safety and feasibility trial of a microbicide/diaphragm combination: an integrated qualitative and quantitative analysis.CrossRef |

[40]  Holmes WR, Maher L, Rosenthal SL. Attitudes of men in an Australian male tolerance study towards microbicide use. Sex Health 2008; 5 273–8.
Attitudes of men in an Australian male tolerance study towards microbicide use.CrossRef |

[41]  McMahon JM, et al Potential impact of vaginal microbicides on HIV risk among women with primary heterosexual partners. J Assoc Nurses AIDS Care 2011; 22 9–16.
Potential impact of vaginal microbicides on HIV risk among women with primary heterosexual partners.CrossRef |

[42]  Chen FH. The impact of microbicides and changes in condom usage on HIV prevalence in men and women. AIDS 2006; 20 1551–3.
The impact of microbicides and changes in condom usage on HIV prevalence in men and women.CrossRef |

[43]  Lurie MN, et al The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners. Sex Transm Dis 2003; 30 149–56.
The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners.CrossRef |

[44]  Sanders S, Yarber WL, Kaufman EL, Crosby RA, Graham CA, Milhausen RR. Condom use errors and problems: a global view. Sex Health 2012; 9 81–95.

[45]  Newman PA, et al Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES). Health Serv Res 2009; 44 2167–79.
Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES).CrossRef |

[46]  Blower SM, McLean AR. Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science 1994; 265 1451–4.
Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco.CrossRef | 1:STN:280:DyaK2czltlantw%3D%3D&md5=835a457764e3ab736393cdd737976c99CAS |

[47]  Jackson DJ, et al Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya. AIDS 1995; 9 1279–84.
Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya.CrossRef | 1:STN:280:DyaK287is1WrsQ%3D%3D&md5=3bea7ca62dcd3ea0bcbf17e23787cfedCAS |

[48]  Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr 1997; 16 266–71.
Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note.CrossRef | 1:STN:280:DyaK1c%2FmtlKltw%3D%3D&md5=026b8694fc30635901f314a89b034c07CAS |

[49]  Blower S, Schwartz EJ, Mills J. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines. AIDS Rev 2003; 5 113–25.
| 1:STN:280:DC%2BD3szksFGqsg%3D%3D&md5=11d6b5ce9be1bb6abefa0ac758093944CAS |

[50]  Newman PA, et al Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come? AIDS Patient Care STDS 2004; 18 691–701.
Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come?CrossRef |

[51]  Fonseca MGP, et al Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV. PLoS ONE 2010; 5 e11736–11736.
Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV.CrossRef |

[52]  Andersson KM, et al Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: a South African example. J Acquir Immune Defic Syndr 2007; 46 78–90.

[53]  Newman PA, et al Posttrial HIV vaccine adoption: concerns, motivators, and intentions among persons at risk for HIV. J Acquir Immune Defic Syndr 2004; 37 1393–403.
Posttrial HIV vaccine adoption: concerns, motivators, and intentions among persons at risk for HIV.CrossRef |

[54]  Newman PA, et al HIV risk and prevention in a post-vaccine context. Vaccine 2004; 22 1954–63.
HIV risk and prevention in a post-vaccine context.CrossRef |

[55]  Suraratdecha C, et al The private demand for an AIDS vaccine in Thailand. Health Policy 2005; 71 271–87.
The private demand for an AIDS vaccine in Thailand.CrossRef |

[56]  Suhadev M, et al Factors associated with willingness to participate in HIV vaccine trials among high-risk populations in South India. AIDS Res Hum Retroviruses 2009; 25 217–24.
Factors associated with willingness to participate in HIV vaccine trials among high-risk populations in South India.CrossRef |

[57]  Crosby RA, Holtgrave DR. Will sexual risk behaviour increase after being vaccinated for AIDS? Int J STD AIDS 2006; 17 180–4.
Will sexual risk behaviour increase after being vaccinated for AIDS?CrossRef |

[58]  Bartholow BN, et al HIV sexual risk behavior over 36 months of follow-up in the world’s first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2005; 39 90–101.
HIV sexual risk behavior over 36 months of follow-up in the world’s first HIV vaccine efficacy trial.CrossRef |

[59]  Guest G, et al HIV vaccine efficacy trial participation: men who have sex with men’s experiences of risk reduction counselling and perceptions of risk behaviour change. AIDS Care 2005; 17 46–57.
HIV vaccine efficacy trial participation: men who have sex with men’s experiences of risk reduction counselling and perceptions of risk behaviour change.CrossRef | 1:STN:280:DC%2BD2M7pvFWntw%3D%3D&md5=dc53ff1728f35d8e5630373ff8f01745CAS |

[60]  Newman PA, et al Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine 2010; 28 958–64.
Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand.CrossRef | 1:CAS:528:DC%2BC3cXntlSlsA%3D%3D&md5=43a793d34898429b2b720525e0818f35CAS |

[61]  Lee SJ, et al HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approach. AIDS Care 2008; 20 1161–8.
HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approach.CrossRef |

[62]  Newman PA, et al Community heroes or “high-risk” pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine 2008; 26 1091–7.
Community heroes or “high-risk” pariahs? Reasons for declining to enroll in an HIV vaccine trial.CrossRef |

[63]  Nyamathi AM, et al Perceptions of a community sample about participation in future HIV vaccine trials in south India. AIDS Behav 2007; 11 619–27.
Perceptions of a community sample about participation in future HIV vaccine trials in south India.CrossRef |

[64]  Crosby RA, Holtgrave D. Will sexual risk behavior increase after being vaccinated for AIDS? Int J STD AIDS 2006; 17 180–4.
Will sexual risk behavior increase after being vaccinated for AIDS?CrossRef |

[65]  Sayles JN, et al Future HIV vaccine acceptability among young adults in South Africa. Health Educ Behav 2010; 37 193–210.
Future HIV vaccine acceptability among young adults in South Africa.CrossRef |

[66]  Newman PA, et al HIV risk and prevention in a post-vaccine context. Vaccine 2004; 22 1954–63.
HIV risk and prevention in a post-vaccine context.CrossRef |

[67]  Lampinen TM, et al Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine. Canadian Medical Association Journal 2005; 172 479–83.
Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine.CrossRef |

[68]  van Griensven F, et al Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS 2004; 18 295–301.
Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand.CrossRef |

[69]  Francis DP, et al Candidate HIV/AIDS vaccines: lessons learned from the world’s first phase III efficacy trials. AIDS 2003; 17 147–56.
Candidate HIV/AIDS vaccines: lessons learned from the world’s first phase III efficacy trials.CrossRef |

[70]  Bishai D, et al Determinants of personal demand for an AIDS vaccine in Uganda: contingent valuation survey. Bull World Health Organ 2004; 82 652–60.

[71]  Crosby R, et al A brief, clinic-based, safer sex intervention for heterosexual African American men newly diagnosed with an STD: a randomized controlled trial. Am J Public Health 2009; 99 S96–103.
A brief, clinic-based, safer sex intervention for heterosexual African American men newly diagnosed with an STD: a randomized controlled trial.CrossRef |

[72]  Darbes L, et al The efficacy of behavioral interventions in reducing HIV risk behaviors and incident sexually transmitted diseases in heterosexual African Americans. AIDS 2008; 22 1177–94.
The efficacy of behavioral interventions in reducing HIV risk behaviors and incident sexually transmitted diseases in heterosexual African Americans.CrossRef |

[73]  Dilley JW, et al Brief cognitive counseling with HIV testing to reduce sexual risk among men who have sex with men: results from a randomized controlled trial using paraprofessional counselors. J Acquir Immune Defic Syndr 2007; 44 569–77.
Brief cognitive counseling with HIV testing to reduce sexual risk among men who have sex with men: results from a randomized controlled trial using paraprofessional counselors.CrossRef |

[74]  Jemmott LS, Jemmott JB, O’Leary A. Effects on sexual risk behavior and STD rate of brief HIV/STD prevention interventions for African American women in primary care settings. Am J Public Health 2007; 97 1034–40.
Effects on sexual risk behavior and STD rate of brief HIV/STD prevention interventions for African American women in primary care settings.CrossRef |

[75]  Jones KT, et al Evaluation of an HIV prevention intervention adapted for Black men who have sex with men. Am J Public Health 2008; 98 1043–50.
Evaluation of an HIV prevention intervention adapted for Black men who have sex with men.CrossRef |

[76]  Lyles CM, et al Best-evidence interventions: findings from a systematic review of HIV behavioral interventions for US populations at high risk, 2000–2004. Am J Public Health 2007; 97 133–43.
Best-evidence interventions: findings from a systematic review of HIV behavioral interventions for US populations at high risk, 2000–2004.CrossRef |

[77]  Rietmeijer CA. Risk reduction counselling for prevention of sexually transmitted infections: how it works and how to make it work. Sex Transm Infect 2007; 83 2–9.
Risk reduction counselling for prevention of sexually transmitted infections: how it works and how to make it work.CrossRef | 1:STN:280:DC%2BD2s%2Fot1ymtg%3D%3D&md5=3badd6b85a7efb3cc0716ca6eff745ebCAS |

[78]  Ward H. One-to-one counselling for STI prevention: not so much whether as how. Sex Transm Infect 2007; 83 1

[79]  U.S. Preventative Services Task Force Behavioral counseling to prevent sexually transmitted infections: US Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149 491–6.

[80]  Koblin B, Chesney M, Coates T. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet 2004; 364 41–50.
Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study.CrossRef | 1:STN:280:DC%2BD2czjtlKrug%3D%3D&md5=5c44381e3ffcb671479ea50f71e37a25CAS |



Rent Article (via Deepdyve) Export Citation Cited By (10)

View Altmetrics